MARY AMEH: Open Payments
NPI 1063881274 · KENNEWICK, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 28 payments from 11 companies in 2025. Trend: 2023 $1,022 · 2024 $349 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 6 | $220 |
| Janssen Pharmaceuticals, Inc | 6 | $212 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| Neurocrine BioSciences, Inc. | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Lundbeck LLC | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
Products named: ARISTADA, INVEGA SUSTENNA, Auvelity, INGREZZA, REXULTI, TRINTELLIX, CAPLYTA, UZEDY.
Industry payments across WA — which companies pay providers there.
